Merck: A Buy For 2026, But The Clock Is Still Ticking [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
The extended exclusivity creates a one-time cash windfall and enables deeper penetration of Keytruda QLEX, potentially adding $10/share in 'hidden alpha.' MRK's 40:30:30 strategy—QLEX migration, pipeline execution, and business development—offers a realistic path to offset Keytruda's eventual decline. With a potential 18% total return in the next year, the delayed patent cliff gives investors more time to monitor MRK's execution and risk profile. Michael Vi/iStock Editorial via Getty Images For years, investors have discounted Merck ( MRK ) due to the coming loss of exclusivity [LOE] for Keytruda in 2028. While headlines from last week's earnings report focused on softer-than-expected guidance, investors may have overlooked a bullish This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of cal
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction [Seeking Alpha]Seeking Alpha
- Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers SymposiumBusiness Wire
- KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS =1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line TreatmentBusiness Wire
- Julien Nono-Womdim's Top Picks for Feb. 10, 2026 [BNN Bloomberg (Canada)]BNN Bloomberg
- Merck: The Spike Doesn't Make It Overvalued [Seeking Alpha]Seeking Alpha
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/10/26 - Form 144
- 2/10/26 - Form 4
- 2/9/26 - Form 144
- MRK's page on the SEC website